Of elucidating speed dating over 50 san francisco

Lee Moffitt Cancer Center), Rajdeep Das, MBBS, Ph D (University of California, San Francisco), Eric Small, MD (University of California, San Francisco), Amrita Basu, Ph D (H.

Lee Moffitt Cancer Center) Project Title: Targeting Androgen Receptor and ACK1 Signaling with Novel Epigenetic Therapeutics in Castration-Resistant Prostate Cancer.

2017 Movember Foundation – Distinguished Gentleman’s Ride – PCF Challenge Award (

2017 Movember Foundation – Distinguished Gentleman’s Ride – PCF Challenge Award ($1 Million) Principal Investigators: Douglas Mc Neel, MD, Ph D (University of Wisconsin) Co-Investigators: Glenn Liu, MD (University of Wisconsin), Robert Jeraj, Ph D (University of Wisconsin), Christos Kyriakopoulos, MD (University of Wisconsin) Project Title: Broadening T-Cell Activation with PD-1 Blockade to Treat Advanced, Metastatic Prostate Cancer Description: What this means to patients: Treatment strategies that effectively activate the immune system to target cancer will provide a promising new therapeutic opportunity for men with prostate cancer. Mc Neel and team will conduct a clinical trial testing the combination of two therapeutic prostate cancer vaccines plus the checkpoint immunotherapy anti-PD1, which may result in an effective new therapy for prostate cancer patients.

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Felix Feng, MD (University of California, San Francisco), Alan Ashworth, Ph D (University of California, San Francisco), Charles Ryan, MD (University of California, San Francisco), Alexander Wyatt, Ph D (University of British Columbia) Co-Investigators: David Quigley, Ph D (University of California, San Francisco), Li Zhang, Ph D (University of California, San Francisco), Wassim Abida, MD, Ph D (Memorial Sloan Kettering Cancer Center), Luke Gilbert, Ph D (University of California, San Francisco) Project Title: Identifying and Overcoming PARP Inhibitor Resistance in Patients with Metastatic Prostate Cancer Description: What this means to patients: PARP-inhibitors are a precision medicine that will likely gain FDA-approval for the treatment of advanced prostate cancer in the next few years. Feng and team will conduct studies that will optimize the use of these agents in patients, by identifying patients who are likely to benefit, uncovering mechanisms of PARP-inhibitor resistance, and discovering new treatments for patients who have progressed on PARP-inhibitors.

With this mechanistic knowledge we try to improve existing catalytic processes and develop new synthetically useful catalytic reactions.

We are particularly interested in the functionalization of unactivated C-H bonds and the reactivity of low-ligated complexes.

The research interest of our group is focussed on the chemistry of transition metal complexes and their use as catalysts for organic reactions.

||

2017 Movember Foundation – Distinguished Gentleman’s Ride – PCF Challenge Award ($1 Million) Principal Investigators: Douglas Mc Neel, MD, Ph D (University of Wisconsin) Co-Investigators: Glenn Liu, MD (University of Wisconsin), Robert Jeraj, Ph D (University of Wisconsin), Christos Kyriakopoulos, MD (University of Wisconsin) Project Title: Broadening T-Cell Activation with PD-1 Blockade to Treat Advanced, Metastatic Prostate Cancer Description: What this means to patients: Treatment strategies that effectively activate the immune system to target cancer will provide a promising new therapeutic opportunity for men with prostate cancer. Mc Neel and team will conduct a clinical trial testing the combination of two therapeutic prostate cancer vaccines plus the checkpoint immunotherapy anti-PD1, which may result in an effective new therapy for prostate cancer patients.2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Felix Feng, MD (University of California, San Francisco), Alan Ashworth, Ph D (University of California, San Francisco), Charles Ryan, MD (University of California, San Francisco), Alexander Wyatt, Ph D (University of British Columbia) Co-Investigators: David Quigley, Ph D (University of California, San Francisco), Li Zhang, Ph D (University of California, San Francisco), Wassim Abida, MD, Ph D (Memorial Sloan Kettering Cancer Center), Luke Gilbert, Ph D (University of California, San Francisco) Project Title: Identifying and Overcoming PARP Inhibitor Resistance in Patients with Metastatic Prostate Cancer Description: What this means to patients: PARP-inhibitors are a precision medicine that will likely gain FDA-approval for the treatment of advanced prostate cancer in the next few years. Feng and team will conduct studies that will optimize the use of these agents in patients, by identifying patients who are likely to benefit, uncovering mechanisms of PARP-inhibitor resistance, and discovering new treatments for patients who have progressed on PARP-inhibitors.With this mechanistic knowledge we try to improve existing catalytic processes and develop new synthetically useful catalytic reactions.We are particularly interested in the functionalization of unactivated C-H bonds and the reactivity of low-ligated complexes.The research interest of our group is focussed on the chemistry of transition metal complexes and their use as catalysts for organic reactions.

Million) Principal Investigators: Douglas Mc Neel, MD, Ph D (University of Wisconsin) Co-Investigators: Glenn Liu, MD (University of Wisconsin), Robert Jeraj, Ph D (University of Wisconsin), Christos Kyriakopoulos, MD (University of Wisconsin) Project Title: Broadening T-Cell Activation with PD-1 Blockade to Treat Advanced, Metastatic Prostate Cancer Description: What this means to patients: Treatment strategies that effectively activate the immune system to target cancer will provide a promising new therapeutic opportunity for men with prostate cancer. Mc Neel and team will conduct a clinical trial testing the combination of two therapeutic prostate cancer vaccines plus the checkpoint immunotherapy anti-PD1, which may result in an effective new therapy for prostate cancer patients.2017 Movember Foundation – PCF Challenge Award (

2017 Movember Foundation – Distinguished Gentleman’s Ride – PCF Challenge Award ($1 Million) Principal Investigators: Douglas Mc Neel, MD, Ph D (University of Wisconsin) Co-Investigators: Glenn Liu, MD (University of Wisconsin), Robert Jeraj, Ph D (University of Wisconsin), Christos Kyriakopoulos, MD (University of Wisconsin) Project Title: Broadening T-Cell Activation with PD-1 Blockade to Treat Advanced, Metastatic Prostate Cancer Description: What this means to patients: Treatment strategies that effectively activate the immune system to target cancer will provide a promising new therapeutic opportunity for men with prostate cancer. Mc Neel and team will conduct a clinical trial testing the combination of two therapeutic prostate cancer vaccines plus the checkpoint immunotherapy anti-PD1, which may result in an effective new therapy for prostate cancer patients.

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Felix Feng, MD (University of California, San Francisco), Alan Ashworth, Ph D (University of California, San Francisco), Charles Ryan, MD (University of California, San Francisco), Alexander Wyatt, Ph D (University of British Columbia) Co-Investigators: David Quigley, Ph D (University of California, San Francisco), Li Zhang, Ph D (University of California, San Francisco), Wassim Abida, MD, Ph D (Memorial Sloan Kettering Cancer Center), Luke Gilbert, Ph D (University of California, San Francisco) Project Title: Identifying and Overcoming PARP Inhibitor Resistance in Patients with Metastatic Prostate Cancer Description: What this means to patients: PARP-inhibitors are a precision medicine that will likely gain FDA-approval for the treatment of advanced prostate cancer in the next few years. Feng and team will conduct studies that will optimize the use of these agents in patients, by identifying patients who are likely to benefit, uncovering mechanisms of PARP-inhibitor resistance, and discovering new treatments for patients who have progressed on PARP-inhibitors.

With this mechanistic knowledge we try to improve existing catalytic processes and develop new synthetically useful catalytic reactions.

We are particularly interested in the functionalization of unactivated C-H bonds and the reactivity of low-ligated complexes.

The research interest of our group is focussed on the chemistry of transition metal complexes and their use as catalysts for organic reactions.

||

2017 Movember Foundation – Distinguished Gentleman’s Ride – PCF Challenge Award ($1 Million) Principal Investigators: Douglas Mc Neel, MD, Ph D (University of Wisconsin) Co-Investigators: Glenn Liu, MD (University of Wisconsin), Robert Jeraj, Ph D (University of Wisconsin), Christos Kyriakopoulos, MD (University of Wisconsin) Project Title: Broadening T-Cell Activation with PD-1 Blockade to Treat Advanced, Metastatic Prostate Cancer Description: What this means to patients: Treatment strategies that effectively activate the immune system to target cancer will provide a promising new therapeutic opportunity for men with prostate cancer. Mc Neel and team will conduct a clinical trial testing the combination of two therapeutic prostate cancer vaccines plus the checkpoint immunotherapy anti-PD1, which may result in an effective new therapy for prostate cancer patients.2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Felix Feng, MD (University of California, San Francisco), Alan Ashworth, Ph D (University of California, San Francisco), Charles Ryan, MD (University of California, San Francisco), Alexander Wyatt, Ph D (University of British Columbia) Co-Investigators: David Quigley, Ph D (University of California, San Francisco), Li Zhang, Ph D (University of California, San Francisco), Wassim Abida, MD, Ph D (Memorial Sloan Kettering Cancer Center), Luke Gilbert, Ph D (University of California, San Francisco) Project Title: Identifying and Overcoming PARP Inhibitor Resistance in Patients with Metastatic Prostate Cancer Description: What this means to patients: PARP-inhibitors are a precision medicine that will likely gain FDA-approval for the treatment of advanced prostate cancer in the next few years. Feng and team will conduct studies that will optimize the use of these agents in patients, by identifying patients who are likely to benefit, uncovering mechanisms of PARP-inhibitor resistance, and discovering new treatments for patients who have progressed on PARP-inhibitors.With this mechanistic knowledge we try to improve existing catalytic processes and develop new synthetically useful catalytic reactions.We are particularly interested in the functionalization of unactivated C-H bonds and the reactivity of low-ligated complexes.The research interest of our group is focussed on the chemistry of transition metal complexes and their use as catalysts for organic reactions.

Million) Principal Investigators: Felix Feng, MD (University of California, San Francisco), Alan Ashworth, Ph D (University of California, San Francisco), Charles Ryan, MD (University of California, San Francisco), Alexander Wyatt, Ph D (University of British Columbia) Co-Investigators: David Quigley, Ph D (University of California, San Francisco), Li Zhang, Ph D (University of California, San Francisco), Wassim Abida, MD, Ph D (Memorial Sloan Kettering Cancer Center), Luke Gilbert, Ph D (University of California, San Francisco) Project Title: Identifying and Overcoming PARP Inhibitor Resistance in Patients with Metastatic Prostate Cancer Description: What this means to patients: PARP-inhibitors are a precision medicine that will likely gain FDA-approval for the treatment of advanced prostate cancer in the next few years. Feng and team will conduct studies that will optimize the use of these agents in patients, by identifying patients who are likely to benefit, uncovering mechanisms of PARP-inhibitor resistance, and discovering new treatments for patients who have progressed on PARP-inhibitors.With this mechanistic knowledge we try to improve existing catalytic processes and develop new synthetically useful catalytic reactions.We are particularly interested in the functionalization of unactivated C-H bonds and the reactivity of low-ligated complexes.The research interest of our group is focussed on the chemistry of transition metal complexes and their use as catalysts for organic reactions.

We investigate the reactivity of transition metal compounds with the aim of elucidating and understanding the elementary steps of a catalytic cycle.

2017 Movember Foundation – PCF Challenge Award (

We investigate the reactivity of transition metal compounds with the aim of elucidating and understanding the elementary steps of a catalytic cycle.2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Joshua Lang, MD (University of Wisconsin), Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Scott Dehm, Ph D (Masonic Cancer Center, University of Minnesota), Scott Tagawa, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Kimberly Ku, MD (University of Wisconsin) Project Title: Therapeutic Targeting of AR Variant Prostate Cancer with a Novel Antibody Drug Conjugate Description: What this means to patients: New treatments are critically needed for patients with advanced prostate cancer. Lang and team will conduct a clinical trial to test whether targeting TROP-2 with a drug-carrying antibody has promise for the treatment of prostate cancer patients and develop biomarkers that can be used to select patients who will benefit from this treatment.2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Chad Mirkin, Ph D (Northwestern University) Co-Investigators: Bin Zhang, MD, Ph D (Northwestern University), Timothy Kuzel, MD (Northwestern University), William Catalona, MD (Northwestern University), Andrew Lee, Ph D (Northwestern University) Project Title: Spherical Nucleic Acids as Therapeutic Vaccines for the Treatment of Prostate Cancer Description: What this means to patients: Therapies that effectively stimulate a person’s immune system to attack and kill tumor cells are highly promising but still underdeveloped in prostate cancer. Mirkin and team will develop and test a novel nanoparticle-based therapeutic prostate cancer vaccine in preclinical models, which may lead to a new immunotherapy for prostate cancer.This team will study prostate cancer samples from US Veterans to better understand the biology of prostate cancer in African-American men and to elucidate the effects of exposure to battlefield chemicals such as Agent Orange on the development and progression of prostate cancer.2017 PCF Challenge Award ($1 Million) Award Donors: Igor Tulchinsky, Milken Family Foundation Principal Investigators: Amina Zoubeidi, Ph D (Vancouver Prostate Centre; Vancouver Coastal Health Research Institute; University of British Columbia), Himisha Beltran, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Robert Young, Ph D (Simon Fraser University), Ravi Munuganti, Ph D (University of British Columbia) Project Title: Targeting BRN2 in Neuroendocrine Prostate Cancer Description: What this means to patients: Neuroendocrine prostate cancer (NEPC) is an aggressive and lethal subtype of prostate cancer that does not respond to hormonal therapy.2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Nupam Mahajan, Ph D (H.

||

We investigate the reactivity of transition metal compounds with the aim of elucidating and understanding the elementary steps of a catalytic cycle.

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Joshua Lang, MD (University of Wisconsin), Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Scott Dehm, Ph D (Masonic Cancer Center, University of Minnesota), Scott Tagawa, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Kimberly Ku, MD (University of Wisconsin) Project Title: Therapeutic Targeting of AR Variant Prostate Cancer with a Novel Antibody Drug Conjugate Description: What this means to patients: New treatments are critically needed for patients with advanced prostate cancer. Lang and team will conduct a clinical trial to test whether targeting TROP-2 with a drug-carrying antibody has promise for the treatment of prostate cancer patients and develop biomarkers that can be used to select patients who will benefit from this treatment.

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Chad Mirkin, Ph D (Northwestern University) Co-Investigators: Bin Zhang, MD, Ph D (Northwestern University), Timothy Kuzel, MD (Northwestern University), William Catalona, MD (Northwestern University), Andrew Lee, Ph D (Northwestern University) Project Title: Spherical Nucleic Acids as Therapeutic Vaccines for the Treatment of Prostate Cancer Description: What this means to patients: Therapies that effectively stimulate a person’s immune system to attack and kill tumor cells are highly promising but still underdeveloped in prostate cancer. Mirkin and team will develop and test a novel nanoparticle-based therapeutic prostate cancer vaccine in preclinical models, which may lead to a new immunotherapy for prostate cancer.

This team will study prostate cancer samples from US Veterans to better understand the biology of prostate cancer in African-American men and to elucidate the effects of exposure to battlefield chemicals such as Agent Orange on the development and progression of prostate cancer.

2017 PCF Challenge Award ($1 Million) Award Donors: Igor Tulchinsky, Milken Family Foundation Principal Investigators: Amina Zoubeidi, Ph D (Vancouver Prostate Centre; Vancouver Coastal Health Research Institute; University of British Columbia), Himisha Beltran, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Robert Young, Ph D (Simon Fraser University), Ravi Munuganti, Ph D (University of British Columbia) Project Title: Targeting BRN2 in Neuroendocrine Prostate Cancer Description: What this means to patients: Neuroendocrine prostate cancer (NEPC) is an aggressive and lethal subtype of prostate cancer that does not respond to hormonal therapy.

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Nupam Mahajan, Ph D (H.

Million) Principal Investigators: Joshua Lang, MD (University of Wisconsin), Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Scott Dehm, Ph D (Masonic Cancer Center, University of Minnesota), Scott Tagawa, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Kimberly Ku, MD (University of Wisconsin) Project Title: Therapeutic Targeting of AR Variant Prostate Cancer with a Novel Antibody Drug Conjugate Description: What this means to patients: New treatments are critically needed for patients with advanced prostate cancer. Lang and team will conduct a clinical trial to test whether targeting TROP-2 with a drug-carrying antibody has promise for the treatment of prostate cancer patients and develop biomarkers that can be used to select patients who will benefit from this treatment.

2017 Movember Foundation – PCF Challenge Award (

We investigate the reactivity of transition metal compounds with the aim of elucidating and understanding the elementary steps of a catalytic cycle.2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Joshua Lang, MD (University of Wisconsin), Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Scott Dehm, Ph D (Masonic Cancer Center, University of Minnesota), Scott Tagawa, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Kimberly Ku, MD (University of Wisconsin) Project Title: Therapeutic Targeting of AR Variant Prostate Cancer with a Novel Antibody Drug Conjugate Description: What this means to patients: New treatments are critically needed for patients with advanced prostate cancer. Lang and team will conduct a clinical trial to test whether targeting TROP-2 with a drug-carrying antibody has promise for the treatment of prostate cancer patients and develop biomarkers that can be used to select patients who will benefit from this treatment.2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Chad Mirkin, Ph D (Northwestern University) Co-Investigators: Bin Zhang, MD, Ph D (Northwestern University), Timothy Kuzel, MD (Northwestern University), William Catalona, MD (Northwestern University), Andrew Lee, Ph D (Northwestern University) Project Title: Spherical Nucleic Acids as Therapeutic Vaccines for the Treatment of Prostate Cancer Description: What this means to patients: Therapies that effectively stimulate a person’s immune system to attack and kill tumor cells are highly promising but still underdeveloped in prostate cancer. Mirkin and team will develop and test a novel nanoparticle-based therapeutic prostate cancer vaccine in preclinical models, which may lead to a new immunotherapy for prostate cancer.This team will study prostate cancer samples from US Veterans to better understand the biology of prostate cancer in African-American men and to elucidate the effects of exposure to battlefield chemicals such as Agent Orange on the development and progression of prostate cancer.2017 PCF Challenge Award ($1 Million) Award Donors: Igor Tulchinsky, Milken Family Foundation Principal Investigators: Amina Zoubeidi, Ph D (Vancouver Prostate Centre; Vancouver Coastal Health Research Institute; University of British Columbia), Himisha Beltran, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Robert Young, Ph D (Simon Fraser University), Ravi Munuganti, Ph D (University of British Columbia) Project Title: Targeting BRN2 in Neuroendocrine Prostate Cancer Description: What this means to patients: Neuroendocrine prostate cancer (NEPC) is an aggressive and lethal subtype of prostate cancer that does not respond to hormonal therapy.2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Nupam Mahajan, Ph D (H.

||

We investigate the reactivity of transition metal compounds with the aim of elucidating and understanding the elementary steps of a catalytic cycle.

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Joshua Lang, MD (University of Wisconsin), Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Scott Dehm, Ph D (Masonic Cancer Center, University of Minnesota), Scott Tagawa, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Kimberly Ku, MD (University of Wisconsin) Project Title: Therapeutic Targeting of AR Variant Prostate Cancer with a Novel Antibody Drug Conjugate Description: What this means to patients: New treatments are critically needed for patients with advanced prostate cancer. Lang and team will conduct a clinical trial to test whether targeting TROP-2 with a drug-carrying antibody has promise for the treatment of prostate cancer patients and develop biomarkers that can be used to select patients who will benefit from this treatment.

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Chad Mirkin, Ph D (Northwestern University) Co-Investigators: Bin Zhang, MD, Ph D (Northwestern University), Timothy Kuzel, MD (Northwestern University), William Catalona, MD (Northwestern University), Andrew Lee, Ph D (Northwestern University) Project Title: Spherical Nucleic Acids as Therapeutic Vaccines for the Treatment of Prostate Cancer Description: What this means to patients: Therapies that effectively stimulate a person’s immune system to attack and kill tumor cells are highly promising but still underdeveloped in prostate cancer. Mirkin and team will develop and test a novel nanoparticle-based therapeutic prostate cancer vaccine in preclinical models, which may lead to a new immunotherapy for prostate cancer.

This team will study prostate cancer samples from US Veterans to better understand the biology of prostate cancer in African-American men and to elucidate the effects of exposure to battlefield chemicals such as Agent Orange on the development and progression of prostate cancer.

2017 PCF Challenge Award ($1 Million) Award Donors: Igor Tulchinsky, Milken Family Foundation Principal Investigators: Amina Zoubeidi, Ph D (Vancouver Prostate Centre; Vancouver Coastal Health Research Institute; University of British Columbia), Himisha Beltran, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Robert Young, Ph D (Simon Fraser University), Ravi Munuganti, Ph D (University of British Columbia) Project Title: Targeting BRN2 in Neuroendocrine Prostate Cancer Description: What this means to patients: Neuroendocrine prostate cancer (NEPC) is an aggressive and lethal subtype of prostate cancer that does not respond to hormonal therapy.

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Nupam Mahajan, Ph D (H.

Million) Principal Investigators: Chad Mirkin, Ph D (Northwestern University) Co-Investigators: Bin Zhang, MD, Ph D (Northwestern University), Timothy Kuzel, MD (Northwestern University), William Catalona, MD (Northwestern University), Andrew Lee, Ph D (Northwestern University) Project Title: Spherical Nucleic Acids as Therapeutic Vaccines for the Treatment of Prostate Cancer Description: What this means to patients: Therapies that effectively stimulate a person’s immune system to attack and kill tumor cells are highly promising but still underdeveloped in prostate cancer. Mirkin and team will develop and test a novel nanoparticle-based therapeutic prostate cancer vaccine in preclinical models, which may lead to a new immunotherapy for prostate cancer.

This team will study prostate cancer samples from US Veterans to better understand the biology of prostate cancer in African-American men and to elucidate the effects of exposure to battlefield chemicals such as Agent Orange on the development and progression of prostate cancer.

2017 PCF Challenge Award (

We investigate the reactivity of transition metal compounds with the aim of elucidating and understanding the elementary steps of a catalytic cycle.2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Joshua Lang, MD (University of Wisconsin), Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Scott Dehm, Ph D (Masonic Cancer Center, University of Minnesota), Scott Tagawa, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Kimberly Ku, MD (University of Wisconsin) Project Title: Therapeutic Targeting of AR Variant Prostate Cancer with a Novel Antibody Drug Conjugate Description: What this means to patients: New treatments are critically needed for patients with advanced prostate cancer. Lang and team will conduct a clinical trial to test whether targeting TROP-2 with a drug-carrying antibody has promise for the treatment of prostate cancer patients and develop biomarkers that can be used to select patients who will benefit from this treatment.2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Chad Mirkin, Ph D (Northwestern University) Co-Investigators: Bin Zhang, MD, Ph D (Northwestern University), Timothy Kuzel, MD (Northwestern University), William Catalona, MD (Northwestern University), Andrew Lee, Ph D (Northwestern University) Project Title: Spherical Nucleic Acids as Therapeutic Vaccines for the Treatment of Prostate Cancer Description: What this means to patients: Therapies that effectively stimulate a person’s immune system to attack and kill tumor cells are highly promising but still underdeveloped in prostate cancer. Mirkin and team will develop and test a novel nanoparticle-based therapeutic prostate cancer vaccine in preclinical models, which may lead to a new immunotherapy for prostate cancer.This team will study prostate cancer samples from US Veterans to better understand the biology of prostate cancer in African-American men and to elucidate the effects of exposure to battlefield chemicals such as Agent Orange on the development and progression of prostate cancer.2017 PCF Challenge Award ($1 Million) Award Donors: Igor Tulchinsky, Milken Family Foundation Principal Investigators: Amina Zoubeidi, Ph D (Vancouver Prostate Centre; Vancouver Coastal Health Research Institute; University of British Columbia), Himisha Beltran, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Robert Young, Ph D (Simon Fraser University), Ravi Munuganti, Ph D (University of British Columbia) Project Title: Targeting BRN2 in Neuroendocrine Prostate Cancer Description: What this means to patients: Neuroendocrine prostate cancer (NEPC) is an aggressive and lethal subtype of prostate cancer that does not respond to hormonal therapy.2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Nupam Mahajan, Ph D (H.

||

We investigate the reactivity of transition metal compounds with the aim of elucidating and understanding the elementary steps of a catalytic cycle.

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Joshua Lang, MD (University of Wisconsin), Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Scott Dehm, Ph D (Masonic Cancer Center, University of Minnesota), Scott Tagawa, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Kimberly Ku, MD (University of Wisconsin) Project Title: Therapeutic Targeting of AR Variant Prostate Cancer with a Novel Antibody Drug Conjugate Description: What this means to patients: New treatments are critically needed for patients with advanced prostate cancer. Lang and team will conduct a clinical trial to test whether targeting TROP-2 with a drug-carrying antibody has promise for the treatment of prostate cancer patients and develop biomarkers that can be used to select patients who will benefit from this treatment.

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Chad Mirkin, Ph D (Northwestern University) Co-Investigators: Bin Zhang, MD, Ph D (Northwestern University), Timothy Kuzel, MD (Northwestern University), William Catalona, MD (Northwestern University), Andrew Lee, Ph D (Northwestern University) Project Title: Spherical Nucleic Acids as Therapeutic Vaccines for the Treatment of Prostate Cancer Description: What this means to patients: Therapies that effectively stimulate a person’s immune system to attack and kill tumor cells are highly promising but still underdeveloped in prostate cancer. Mirkin and team will develop and test a novel nanoparticle-based therapeutic prostate cancer vaccine in preclinical models, which may lead to a new immunotherapy for prostate cancer.

This team will study prostate cancer samples from US Veterans to better understand the biology of prostate cancer in African-American men and to elucidate the effects of exposure to battlefield chemicals such as Agent Orange on the development and progression of prostate cancer.

2017 PCF Challenge Award ($1 Million) Award Donors: Igor Tulchinsky, Milken Family Foundation Principal Investigators: Amina Zoubeidi, Ph D (Vancouver Prostate Centre; Vancouver Coastal Health Research Institute; University of British Columbia), Himisha Beltran, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Robert Young, Ph D (Simon Fraser University), Ravi Munuganti, Ph D (University of British Columbia) Project Title: Targeting BRN2 in Neuroendocrine Prostate Cancer Description: What this means to patients: Neuroendocrine prostate cancer (NEPC) is an aggressive and lethal subtype of prostate cancer that does not respond to hormonal therapy.

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Nupam Mahajan, Ph D (H.

Million) Award Donors: Igor Tulchinsky, Milken Family Foundation Principal Investigators: Amina Zoubeidi, Ph D (Vancouver Prostate Centre; Vancouver Coastal Health Research Institute; University of British Columbia), Himisha Beltran, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Robert Young, Ph D (Simon Fraser University), Ravi Munuganti, Ph D (University of British Columbia) Project Title: Targeting BRN2 in Neuroendocrine Prostate Cancer Description: What this means to patients: Neuroendocrine prostate cancer (NEPC) is an aggressive and lethal subtype of prostate cancer that does not respond to hormonal therapy.

2017 Movember Foundation – PCF Challenge Award (

We investigate the reactivity of transition metal compounds with the aim of elucidating and understanding the elementary steps of a catalytic cycle.2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Joshua Lang, MD (University of Wisconsin), Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Scott Dehm, Ph D (Masonic Cancer Center, University of Minnesota), Scott Tagawa, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Kimberly Ku, MD (University of Wisconsin) Project Title: Therapeutic Targeting of AR Variant Prostate Cancer with a Novel Antibody Drug Conjugate Description: What this means to patients: New treatments are critically needed for patients with advanced prostate cancer. Lang and team will conduct a clinical trial to test whether targeting TROP-2 with a drug-carrying antibody has promise for the treatment of prostate cancer patients and develop biomarkers that can be used to select patients who will benefit from this treatment.2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Chad Mirkin, Ph D (Northwestern University) Co-Investigators: Bin Zhang, MD, Ph D (Northwestern University), Timothy Kuzel, MD (Northwestern University), William Catalona, MD (Northwestern University), Andrew Lee, Ph D (Northwestern University) Project Title: Spherical Nucleic Acids as Therapeutic Vaccines for the Treatment of Prostate Cancer Description: What this means to patients: Therapies that effectively stimulate a person’s immune system to attack and kill tumor cells are highly promising but still underdeveloped in prostate cancer. Mirkin and team will develop and test a novel nanoparticle-based therapeutic prostate cancer vaccine in preclinical models, which may lead to a new immunotherapy for prostate cancer.This team will study prostate cancer samples from US Veterans to better understand the biology of prostate cancer in African-American men and to elucidate the effects of exposure to battlefield chemicals such as Agent Orange on the development and progression of prostate cancer.2017 PCF Challenge Award ($1 Million) Award Donors: Igor Tulchinsky, Milken Family Foundation Principal Investigators: Amina Zoubeidi, Ph D (Vancouver Prostate Centre; Vancouver Coastal Health Research Institute; University of British Columbia), Himisha Beltran, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Robert Young, Ph D (Simon Fraser University), Ravi Munuganti, Ph D (University of British Columbia) Project Title: Targeting BRN2 in Neuroendocrine Prostate Cancer Description: What this means to patients: Neuroendocrine prostate cancer (NEPC) is an aggressive and lethal subtype of prostate cancer that does not respond to hormonal therapy.2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Nupam Mahajan, Ph D (H.

||

We investigate the reactivity of transition metal compounds with the aim of elucidating and understanding the elementary steps of a catalytic cycle.

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Joshua Lang, MD (University of Wisconsin), Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Scott Dehm, Ph D (Masonic Cancer Center, University of Minnesota), Scott Tagawa, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Kimberly Ku, MD (University of Wisconsin) Project Title: Therapeutic Targeting of AR Variant Prostate Cancer with a Novel Antibody Drug Conjugate Description: What this means to patients: New treatments are critically needed for patients with advanced prostate cancer. Lang and team will conduct a clinical trial to test whether targeting TROP-2 with a drug-carrying antibody has promise for the treatment of prostate cancer patients and develop biomarkers that can be used to select patients who will benefit from this treatment.

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Chad Mirkin, Ph D (Northwestern University) Co-Investigators: Bin Zhang, MD, Ph D (Northwestern University), Timothy Kuzel, MD (Northwestern University), William Catalona, MD (Northwestern University), Andrew Lee, Ph D (Northwestern University) Project Title: Spherical Nucleic Acids as Therapeutic Vaccines for the Treatment of Prostate Cancer Description: What this means to patients: Therapies that effectively stimulate a person’s immune system to attack and kill tumor cells are highly promising but still underdeveloped in prostate cancer. Mirkin and team will develop and test a novel nanoparticle-based therapeutic prostate cancer vaccine in preclinical models, which may lead to a new immunotherapy for prostate cancer.

This team will study prostate cancer samples from US Veterans to better understand the biology of prostate cancer in African-American men and to elucidate the effects of exposure to battlefield chemicals such as Agent Orange on the development and progression of prostate cancer.

2017 PCF Challenge Award ($1 Million) Award Donors: Igor Tulchinsky, Milken Family Foundation Principal Investigators: Amina Zoubeidi, Ph D (Vancouver Prostate Centre; Vancouver Coastal Health Research Institute; University of British Columbia), Himisha Beltran, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Robert Young, Ph D (Simon Fraser University), Ravi Munuganti, Ph D (University of British Columbia) Project Title: Targeting BRN2 in Neuroendocrine Prostate Cancer Description: What this means to patients: Neuroendocrine prostate cancer (NEPC) is an aggressive and lethal subtype of prostate cancer that does not respond to hormonal therapy.

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Nupam Mahajan, Ph D (H.

Million) Principal Investigators: Nupam Mahajan, Ph D (H.